ParaZero Demonstrates 50 Successful DropAir Deployments as Part of a Decisive Reproducibility Test
A reproducibility test verifies that a system performs consistently and reliably. In aerospace and defense applications, this level of precision is not just an advantage—it's a critical standard. This test verified the scenario of blood transfusion deliveries in operational settings.
The DropAir system is engineered for autonomous, precision delivery in complex environments, including the transport of essential medical supplies, tactical gear, and other sensitive payloads. Its compact and covert design offers unparalleled operational flexibility and mission confidence.
'This successful test demonstrates DropAir's reliability and proves its readiness for real-world missions,' said Boaz Shetzer, CEO of ParaZero. 'Whether for military, humanitarian, or medical use, the system's ability to repeat precise deliveries, time after time, means operators can count on it in critical environments.'
Learn more about DropAir by ParaZero: www.parazero.com/dropair
About ParaZero Technologies
ParaZero (Nasdaq: PRZO) is an aerospace company focused on safety systems for commercial unmanned aerial systems and counter UAS systems. Started in 2014 by a passionate group of aviation professionals and drone industry veterans, ParaZero designs smart, autonomous parachute safety systems designed to enable safe flight operations over populated areas and beyond-visual-line-of-sight (BVLOS) as well as for various military applications including Counter UAS. For more information about ParaZero, please visit https://parazero.com/.
Forward-Looking Statements
This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates' and similar expressions or variations of such words are intended to identify forward-looking statements. For example, ParaZero is using forward-looking statements when it discusses the DropAir system's ability to repeat precise deliveries, time after time, means operators can count on it in critical environments. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission ('SEC'), including, but not limited to, the risks detailed in the Company's Annual Report on Form 20-F filed with the SEC on March 21, 2025. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. ParaZero is not responsible for the content of third-party websites.
Investor Relations Contact:
Michal EfratyInvestor Relationsmichal@efraty.com
ParaZero Technologies Ltd. | 1st HaTachana St.
Kfar Saba, Israel 4453001
P: +972-502753666 | E: contact@parazero.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Micron Technology, Inc. (MU) Launches Industry's Highest-Density, Radiation-Tolerant SLC NAND Flash Memory
By earning a spot on Ethisphere's 2025 list of the World's Most Ethical Companies and attracting significant hedge fund interest, Micron Technology, Inc. (NASDAQ:MU) secures a place on our list of the . Copyright: believeinme33 / 123RF Stock Photo With rapid growth acceleration in the space economy, Micron Technology, Inc. (NASDAQ:MU) announced the launch of the industry's highest-density, radiation-tolerant SLC NAND flash memory on July 22, 2025. This memory chip is designed to survive space's harsh environment, marked by radiation, extreme temperatures, and vacuum pressure. This makes the chip well-suited for advanced space missions. With its memory technology already being used successfully in space, notably in NASA's EMIT spectrometer mission, Micron Technology, Inc. (NASDAQ:MU) aims to expand its aerospace reach with this launch, supporting AI-driven, autonomous spacecraft with effective data storage solutions. Micron Technology, Inc. (NASDAQ:MU) is the only major U.S.-based memory maker, delivering advanced DRAM, NAND, and NOR solutions with its Micron and Crucial brands. It is one of the best ESG stocks. While we acknowledge the potential of MU as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 14 Cheap Transportation Stocks to Buy According to Analysts and Top 10 AI Infrastructure Stocks to Buy Now. Disclosure: None.
Forbes
3 hours ago
- Forbes
Israeli Startups Using AI To Accelerate Drug Discovery
AI Aiding in drug discovery Israel-based AION Labs wants to drive AI to revolutionize pharmaceutical drug discovery and development. AION is an innovative venture that brings together pharmaceutical heavyweights—Pfizer, AstraZeneca, Teva, and Merck—with entrepreneurial scientists, technology leaders, and successful investors. 'We are a venture studio that builds startups using computational technologies and artificial intelligence to unleash new capabilities to discover and develop new drugs with a venture model that we invented,' says Mati Gill, CEO of AION. This unique collaboration addresses a costly endeavor that is crucial to the quality of our lives. It takes $5 billion and ten years to bring a new drug to market. The world's top 20 pharmaceutical companies collectively spent $145 billion on R&D in 2022-23, according to a recent Deloitte report, which also noted 'AI is yet to become a 'game-changer' in pharma R&D.' A more comprehensive survey of 4,191 pharmaceutical companies worldwide, published in Nature Reviews Drug Discovery, found that they spent $276 billion on R&D in 2021. These R&D expenses have increased tenfold since the 1980s (after adjusting for inflation), and pharmaceutical companies now allocate approximately 25% of their revenue to R&D, nearly double the share seen in the early 2000s, according to CB Insights. 'AI could potentially cut years off the discovery process and compress clinical trial times by up to 30%. This would accelerate the delivery of new treatments to patients, unlock novel treatment approaches, and enable more personalized medicine,' noted CBI. Another CBI report, on the AI readiness of pharmaceutical companies, highlighted the importance of external collaboration, 'as breakthrough innovations increasingly emerge from partnerships rather than internal development alone.' Gill predicts that by 2030, the first truly AI-designed drugs will reach regulatory approval. He believes that Israel is uniquely positioned to be a leading ecosystem in transforming the global biotech and pharmaceutical landscape, given its strengths in multidisciplinary scientific discovery, entrepreneurial innovation, computational biology and big data analysis, as well as a robust and integrated healthcare system, and strong government support. 'For the first time, Israel's strengths are coinciding with what the future of the industry is going to be,' says Gill. There are three core principles behind every startup that AION selects and supports, explains Gill: they address a validated, well-defined, industry-wide problem statement; there's a multidisciplinary team that has expertise in both AI and biology and a technology that can solve that problem statement; and that at least one of AION' pharmaceutical partners is willing to commit to working with the startup to initially develop their technology and conduct with them a proof-of-concept at an early stage. The R&D teams of AION Labs' partners help select the specific industry-wide challenges to focus on and the technologies and scientist-led startups that will develop the solutions. To accomplish that, AION has established two tracks, one starting with the problem statement and the other starting with the technology. DenovAI is an example of starting with the problem statement. Is it possible to design proteins 'de novo' or completely from scratch? 'We ran a challenge and had 15 great candidates,' recounts Gill. 'We selected a senior scientist who had developed a technology called AlphaDesign that is basically doing the inverse of the famous AlphaFold.' The startup recently demonstrated its ability to generate new proteins with measurable, targeted function. Its AI-based platform for rapid de novo antibody discovery could reduce the discovery process from months to days, and broaden the scope of therapy to a wide range of diseases. Cassidy Bio is an example of starting with the technology. It is using large language models or LLMs to design new guide RNAs, unlocking the capability of gene therapy in a scalable and precise manner. Guide RNAs or gRNAs serve as the 'GPS' for CRISPR systems, directing the editing machinery to precise genetic targets. The design of gRNAs plays a critical role in determining both the efficacy and safety of gene-editing therapeutics. Professor Ayal Hendel of Israel's Bar-Ilan University, a leading expert in genome editing and gene therapy, teamed up with two experienced entrepreneurs to establish the startup. With AION Labs' help, they raised $8 million in seed funding and are working with AstraZeneca to validate their technology. Based on proprietary, clinically relevant genomic data generation, state-of-the-art predictive algorithms, and rigorous wet lab validation, Cassidy Bio is developing the first comprehensive predictive platform based on LLMs for gRNA design. Unlike the data driving AI consumer applications, which is mostly based on internet-scraped data, pharmaceutical data is proprietary data. AION Labs' unique collaborative model provides access to pharmaceutical firms' R&D teams and their data, along with a secure sharing environment facilitated by AION's tech partner, Amazon's cloud service. This means the pharmaceutical companies can share their proprietary data with the startups in AION Labs' portfolio, but not with each other. AION Labs is also a member of Israel's 8400 The Health Network. This network was founded in 2017 on the premise that HealthTech is Israel's next economic growth engine and that Israel has what it takes to become a game-changing player in the global HealthTech revolution, according to its CEO, Ari Strasberg. To date, the non-profit organization has developed numerous programs and national initiatives, ranging from HealthIL, which bridges the gap between healthcare systems and technology by facilitating over 1,300 pilots and implementing 160 projects, to Helix, which strengthens the working relationships between 46 top U.S. and Israeli HealthTech leaders. The organization has been very successful, says Strasberg, in creating a public-private partnership, connecting government programs with 'the needs of the ecosystem.' Another success story is the development of FIRE, the data interoperability standard used by the healthcare systems in Israel. Going forward, Strasberg would like 8400 to play a major role in increasing the number of very successful Israeli HealthTech startups. 'We have a few, but not enough,' says Strasberg. 'We need to have a few blockbuster ones that carry the entire ecosystem with them.'
Yahoo
7 hours ago
- Yahoo
Man Utd outcast Antony 'open' to joining Cristiano Ronaldo in Saudi Pro League as 'several clubs' ask transfer questions of Brazilian winger
Brazilian enjoyed productive loan at Betis Red Devils willing to listen to offers Could embrace riches in the Middle East Follow GOAL on WhatsApp! 🟢📱 WHAT HAPPENED? The Brazil international has not travelled to the United States as part of Ruben Amorim's plans for a pre-season tour. He is expected to seal another move away from Old Trafford in the summer transfer window. THE BIGGER PICTURE United allowed Antony to link up with Real Betis in January, with a productive loan spell in Spain delivering nine goals and five assists. His exploits there have attracted admiring glances from around the world. DID YOU KNOW? Betis were keen to get another deal done, but lack the funds required to agree a permanent transfer. United need to make at least £32.58 million ($44m) on a player that they signed for £85m ($114m) in order to avoid making a loss under Profit and Sustainability Rules (PSR). WHAT ANTONY'S AGENT SAID Teams in the Middle East would have no problem meeting that asking price, with Antony's representative Junior Pedroso telling WinWin: "What I can say is that the player is on the market, and there are several clubs that want to know his current status. We listen to the projects and analyse them. But he is open to moving to Saudi Arabia. Anything is possible, we are looking for what is best for him." WHAT NEXT? Antony is under contract with United until 2027, with the option for a 12-month extension beyond that point. He is one of several players that Amorim is looking to move on, with fellow winger Marcus Rashford having already left for Barcelona.
